S&P 500: 681.75 +0.1% NASDAQ 100: 601.92 +0.2% Dow Jones: 495.28 +0.1%

Catherine Wood’s PRME Holdings & Trades

First Buy
Q4 2022
Duration Held
13 Quarters
Largest Add
Q3 2025
+3.16 M Shares
Current Position
5.37 M Shares
$18.63 M Value

Catherine Wood's PRME Position Overview

Catherine Wood (via Ark Investment Management LLC) currently holds 5.37 M shares of Prime Medicine, Inc. (PRME) worth $18.63 M, representing 0.12% of the portfolio. First purchased in 2022-Q4, this medium-term investment has been held for 13 quarters.

Based on 13F filings, Catherine Wood has maintained a strategic position in PRME, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2025, adding 3.16 M shares. Largest reduction occurred in Q1 2025, reducing 2.06 M shares.

Analysis based on 13F filings available since 2013 Q2

Catherine Wood's Prime Medicine (PRME) Holding Value Over Time

Track share changes against reported price movement

Quarterly Prime Medicine (PRME) Trades by Catherine Wood

Report Date Bought/Sold (Sh.) % Change Qtr. End Shares Reported Price
Q4 2022 +1.64 M New Buy 1.64 M $18.58
Q1 2023 +282,293 Add 17.21% 1.92 M $12.30
Q2 2023 +526,922 Add 27.41% 2.45 M $14.65
Q3 2023 +173,230 Add 7.07% 2.62 M $9.54
Q4 2023 +515,841 Add 19.67% 3.14 M $8.86
Q1 2024 +2.86 M Add 90.98% 5.99 M $7.00
Q2 2024 +133,419 Add 2.23% 6.13 M $5.14
Q3 2024 -466,054 Reduce 7.61% 5.66 M $3.87
Q4 2024 -510,486 Reduce 9.02% 5.15 M $2.92
Q1 2025 -2.06 M Reduce 39.90% 3.1 M $1.99
Q2 2025 -772,503 Reduce 24.96% 2.32 M $2.47
Q3 2025 +3.16 M Add 135.84% 5.48 M $5.54
Q4 2025 -109,325 Reduce 2.00% 5.37 M $3.47

Catherine Wood's Prime Medicine Investment FAQs

Catherine Wood first purchased Prime Medicine, Inc. (PRME) in Q4 2022, acquiring 1,639,984 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.

Catherine Wood has held Prime Medicine, Inc. (PRME) for 13 quarters since Q4 2022.

Catherine Wood's largest addition to Prime Medicine, Inc. (PRME) was in Q3 2025, adding 5,477,851 shares worth $30.35 M.

According to the latest 13F filing for Q4 2025, Catherine Wood's firm, Ark Investment Management LLC, owns 5,368,526 shares of Prime Medicine, Inc. (PRME), valued at approximately $18.63 M.

As of the Q4 2025 filing, Prime Medicine, Inc. (PRME) represents approximately 0.12% of Catherine Wood's publicly disclosed stock portfolio, making it one of their key holdings.

Catherine Wood's peak holding in Prime Medicine, Inc. (PRME) was 6,126,773 shares, as reported at the end of Q2 2024.